Standard in the clinical management of the lymph metastasis in pancreatic cancer

doi:10.3969/j.issn.1007-3969.2014.02.001

China Oncology ›› 2014, Vol. 24 ›› Issue (2): 81-86.doi: 10.3969/j.issn.1007-3969.2014.02.001

Standard in the clinical management of the lymph metastasis in pancreatic cancer

LUO Guo-pei^1,2,XIAO Zhi-wen^1,2,LIU Zu-qiang^1,2,GUO Meng^1,2,LONG Jiang^1,2,LIU Chen^1,2,LIU Liang^1,2,XU Jin^1,2,NI Quan-xing^1,2,YU Xian-jun^1,2

Department of Pancreas and Hepatobiliary Surgery, Pancreas Cancer Institute, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University; China Anti-cancer Association Pancreatic Cancer Committee, Shanghai 200032, China

Online:2014-02-28 Published:2014-03-07
Contact: YU Xian-jun E-mail: yuxianjun88@hotmail.com

Abstract

Abstract:

Lymph metastasis has great impact on the prognosis of pancreatic cancer patients, which canreflect the biological and invasive potential of pancreatic cancer. However, currently, there is no standard in the clinical management of the lymph metastasis in pancreatic cancer. In this report, we will discuss and summarize the followings: lymph metastatic rate and its impact on prognosis, the rule of lymph metastasis, sentinel lymph node, intra-operative lymph nodes mapping, TNM staging, regional lymph nodes resection, number of lymph nodes examined, lymph node ratio, guiding adjuvant treatments, lymphatic targeted therapy.

Key words: Pancreatic cancer, Lymph metastasis, Diagnosis and treatment, Standard

LUO Guo-pei,XIAO Zhi-wen,LIU Zu-qiang,GUO Meng,LONG Jiang,LIU Chen,LIU Liang,XU Jin,NI Quan-xing,YU Xian-jun. Standard in the clinical management of the lymph metastasis in pancreatic cancer[J]. China Oncology, 2014, 24(2): 81-86.

[1]	ZHU Xinzhe, LI Hao, XU Huaxiang, LUO Guopei, YU Xianjun. Advances in basic research, clinical diagnosis and treatment of pancreatic cancer in 2021 [J]. China Oncology, 2022, 32(1): 1-12.
[2]	Tumor Support and Rehabilitation Therapy Group, the Oncology Committee of Chinese Medical Association. Clinical practice guidelines for cancer-related fatigue in China (2021 edition) [J]. China Oncology, 2021, 31(9): 852-872.
[3]	YANG Shipeng , LIU Ying , WANG Xinyue , YANG Yang , QUAN Jishu , LIN Zhenhua . Clinical significance of PKLR overexpression in the pancreatic cancer [J]. China Oncology, 2021, 31(8): 704-713.
[4]	JIANG Tingting, TANG Wei, YOU Chao, XIAO Qin, SHEN Xigang, PENG Weijun, GU Yajia. Diagnostic value of dual mode digital breast tomosynthesis in breast diseases [J]. China Oncology, 2021, 31(10): 912-919.
[5]	TANG Rong, SHI Si, ZHANG Bo, XU Jin, WANG Wei, YU Xianjun. Advances in basic research, clinical diagnosis and treatment of pancreatic cancer in 2020 [J]. China Oncology, 2021, 31(1): 1-10.
[6]	ZHANG Xiaomeng , MA Ningyi , ZHU Hongcheng , AI Dashan , REN Zhigang . Efficacy and prognostic factors of adjuvant radiotherapy combined with chemotherapy in patients with pancreatic cancer [J]. China Oncology, 2020, 30(7): 519-524.
[7]	MAO Tiebo, CUI Jiujie, WANG Liwei. Research progress in pancreatic cancer in 2019 from experimental study to clinical evaluation [J]. China Oncology, 2020, 30(2): 81-89.
[8]	NING Zhouyu, HUA Yongqiang, XU Litao, ZHUANG Liping, FENG Lanyun, CHEN Hao, WANG Peng, SHEN Yehua, LIN Junhua, CHEN Zhen, MENG Zhiqiang. Efficacy and safety of nab-paclitaxel plus gemcitabine in the treatment of advanced pancreatic cancer by transcatheter arterial chemotherapy: a retrospective study [J]. China Oncology, 2020, 30(2): 128-134.
[9]	PAN Zeyan, ZHAN Xianbao. Current status and future strategies of chimeric antigen receptor T-cells in the treatment of pancreatic cancer [J]. China Oncology, 2019, 29(7): 481-485.
[10]	ZHU Xuqin,JIA Songlin,QI Jie,SHEN Xuefang,LONG Jiang,MIAO Changhong . Perioperative factors associated with prognosis of patients after radical resection of pancreatic cancer: a retrospective analysis [J]. China Oncology, 2019, 29(7): 521-527.
[11]	JIAO Zhikai, FENG Ningning, ZHANG Yueshan, KANG Xi, YANG Baoming, LI Jiankun, CAO Heng, DONG Biao, FU Jionghui, WANG Shunxiang. Expression of miR-762 in pancreatic cancer and its effect on biological behavior of pancreatic cancer cells [J]. China Oncology, 2019, 29(11): 869-874.
[12]	YANG Chao, LUO Guopei, LIU Chen, et al. Advances in basic research, clinical diagnosis and treatment of pancreatic cancer in 2018 [J]. China Oncology, 2019, 29(1): 1-8.
[13]	GAO Qi, GUO Yan, WEI Xiaojuan. The inhibitory effects of celastrol on proliferation, invasion and migration of human pancreatic cancer cell line PANC-1 [J]. China Oncology, 2019, 29(1): 26-31.
[14]	JIN Kaizhou, LUO Guopei, HUANG Qiuyi, et al. The role of endoscopic ultrasound technique in the diagnosis and treatment of pancreatic adenocarcinoma [J]. China Oncology, 2019, 29(1): 52-56.
[15]	ZHANG Shirong, JIN Wei, LIU Liang, et al. Recent advances in basic research, clinical diagnosis and treatment of pancreatic cancer in 2017 [J]. China Oncology, 2018, 28(1): 1-10.

Standard in the clinical management of the lymph metastasis in pancreatic cancer

PDF

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments